Japan Biotech Innovation Showcase & Reception: New Technology Platform Opportunities
Thursday, June 27 2013
4:00 pm – 5:00 pm
Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA
Japan is known for its strength in fundamental life science technology discoveries. One example of these Japan-grown technology “seeds” is iPS cells, invented by 2012 Nobel Prize winner Professor Shinya Yamanaka, which is opening up new possibilities for groundbreaking treatments via both cell therapy and discovery platforms. However, iPSC is not the only innovative life science technology coming out of Japan.
This seminar will present an overview of the current state of the Japanese biotech landscape and discuses some early stage home-grown technology platform companies that have been getting attention from the Big Pharma community.
It will also showcase presentations by three innovative Japanese biotech platform technology companies who have recently brought their technologies to the US.
- Goro Takeda, Venture Partner, Sofinnova Ventures
“The current state of Japanese Biotech – new generation of home-grown discovery platform companies”
Company presentations by:
1) Human Metabolome Technologies (HMT)
Presentations will be followed by a networking reception 5-6pm.
Goro Takeda, Venture Partner, Sofinova Ventures
Goro Takeda joined Sofinnova Ventures in 2007 as a Kauffman Venture Fellow with a focus on identifying Life Science spin-out opportunities in Asia. Goro holds the honor of being the first person from Japan to be selected as a Kauffman Venture Fellow. He is also a co-founder of FinTech Global Capital, an early stage venture capital firm in Tokyo, where he currently serves as Managing Partner.
Before arriving at Sofinnova Ventures, Goro was the Deputy General Manager of NIF SMBC Ventures, a Japanese venture capital firm with $2 billion under management. Goro was responsible for life science investments across multiple geographic regions. Goro was involved with investments in biotechnology and specialty pharmaceutical companies including Arrow Therapeutics, Cyclacel Pharmaceuticals, and Orexigen Therapeutics. Prior to launching his career in venture capital, Goro spent nine years in the pharmaceutical industry, most recently as Corporate Officer of the U.S. subsidiary of Tanabe Pharmaceuticals. While in this position, Goro worked on global business development and marketing assignments.
For more information contact:
Rachel Winograd, JETRO